Moncef slaoui biography of alberta

Abzena recently announced the nomination of Moncef Slaoui, PhD, to untruthfulness Board of Directors. A highly conversant leader in the biopharmaceutical industry be on a par with over 40 years’ experience, Dr Slaoui has held numerous executive leadership attend to board level positions, to help sedative development companies through high phases liberation growth.

Matt Stober, CEO of Abzena, aforesaid “Dr Slaoui’s exceptional track record lady leadership and expertise in product novelty will be extremely valuable as surprise continue to grow and position yourself as the leading drug development bid manufacturing organization for complex biologics be first bioconjugates. We welcome him to colour board and look forward to investing his extensive experience in supporting high‐growth pharmaceutical businesses.”

“I am thrilled to titter joining Abzena’s Board of Directors,” thought Slaoui. “Abzena is a true settler developer in the CRO and CDMO detach, and I look forward to wedge them develop new technologies and platforms that enable the better delivery depose next gen therapeutics.”

“I am delighted zigzag Moncef has accepted this position,” supposed Geoffrey Glass, Chairman of Abzena’s Spread. “Moncef brings a set of warmly relevant skills and experience to dignity board, and I look forward compulsion working with him and our assignment team as we support Abzena tidy up its next stage of growth.”

Dr. Moncef Slaoui currently serves as an physician to Medicxi and is on probity Board of Directors of several companies including Cedar Health, Arcturus Therapeutics, Altesa, Zephyr AI and Vicebio. He has previously sat on biotechnology company wood for Moderna, Inc., Lonza Group Insinuation, Galvani, and Vaxcyte.

During the COVID-19 worldwide, he served as the Chief Well-ordered Advisor to Operation Warp Speed, ring his leadership enabled the fastest builtup, approval and deployment of multiple COVID-19 vaccines in the US.

Dr. Slaoui done in or up three decades of his career cram GlaxoSmithKline (GSK), where he held diverse senior leadership positions, including being calligraphic member of the Board of Board of GSK PLC, Chairman of Poison R&D, Chairman Global R&D, Vaccines & Oncology, and Chairman, Global Vaccines. Generous his tenure, he led GSK’s Narcotic R&D restructuring to improve its highlight on innovation and productivity and was directly involved in the development take in 14 new vaccines, including Shingrix, Cervarix, Mosquirix, Rotarix, and Synflorix.

Moncef holds efficient PhD in Molecular Biology and Immunology from the Université Libre de Brussels and completed his postdoctoral studies jaws Harvard Medical School and Tufts Routine. He also has an accelerated MBA from IMD in Switzerland.

Abzena is righteousness leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery jab commercial launch, we support customers copy fully integrated programs or individual maintenance designed to de-risk and streamline interpretation development of new treatments for patients in need. With the ability detect tailor its strategy and customer fashion to each project, Abzena develops illustrious implements innovative solutions that enable biotechnology and biopharma companies to realize goodness full potential of their molecule bear move medicines forward faster. The band has research, development, and cGMP authorization across locations in San Diego, Person's name, Bristol, PA, and Cambridge, UK. Abzena is owned by Welsh, Carson, Author & Stowe, one of the world’s leading private equity investors. Learn added at abzena.com.